Document Detail

In vitro susceptibilities of yeast species to fluconazole and voriconazole as determined by the 2010 National China Hospital Invasive Fungal Surveillance Net (CHIF-NET) study.
MedLine Citation:
PMID:  23035204     Owner:  NLM     Status:  MEDLINE    
We conducted active, laboratory-based surveillance for isolates from patients with invasive infections across China from August 2009 to July 2010. DNA sequencing methods were used to define species, and susceptibility to fluconazole and voriconazole was determined by the Clinical and Laboratory Standards Institute M44-A2 disk diffusion method but using up-to-date clinical breakpoints or epidemiological cutoff values. Candida spp. made up 90.5% of the 814 yeast strains isolated, followed by Cryptococcus neoformans (7.7%) and other non-Candida yeast strains (1.7%). Bloodstream isolates made up 42.9% of the strains, isolates from ascitic fluid made up 22.1%, but pus/tissue specimens yielded yeast strains in <5% of the cases. Among the Candida isolates, Candida albicans was the most common species from specimens other than blood (50.1%) but made up only 23% of the bloodstream isolates (P < 0.001). C. parapsilosis complex species were the most common Candida isolates from blood (33.2%). Uncommon bloodstream yeast strains included Trichosporon spp., C. pelliculosa, and the novel species C. quercitrusa, reported for the first time as a cause of candidemia. Most (>94%) of the isolates of C. albicans, C. tropicalis, and the C. parapsilosis complex were susceptible to fluconazole and voriconazole, as were all of the Trichosporon strains; however, 12.2% of the C. glabrata sensu stricto isolates were fluconazole resistant and 17.8% had non-wild-type susceptibility to voriconazole. Seven C. tropicalis strains were cross-resistant to fluconazole and voriconazole; six were from patients in the same institution. Resistance to fluconazole and voriconazole was seen in 31.9% and 13.3% of the uncommon Candida and non-Candida yeast strains, respectively. Causative species and azole susceptibility varied with the geographic region. This study provided clinically useful data on yeast strains and their antifungal susceptibilities in China.
He Wang; Meng Xiao; Sharon C-A Chen; Fanrong Kong; Zi-Yong Sun; Kang Liao; Juan Lu; Hai-Feng Shao; Yan Yan; Hong Fan; Zhi-Dong Hu; Yun-Zhuo Chu; Tie-Shi Hu; Yu-Xing Ni; Gui-Ling Zou; Ying-Chun Xu
Related Documents :
22259214 - Phenotypic screening of carbapenemases and associated β-lactamases in carbapenem-resis...
21825644 - Ultra-high sensitivity of super carbon-nanotube-based mass and strain sensors.
8065274 - Murein types in bifidobacterium ruminantium, bifidobacterium merycicum and bifidobacter...
16099674 - Phylogenetic analysis as a tool in molecular epidemiology of infectious diseases.
20655094 - Microbial and antibiotic resistant constituents associated with biological aerosols and...
20485514 - Identification of a mutant pfcrt-mediated chloroquine tolerance phenotype in plasmodium...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2012-10-03
Journal Detail:
Title:  Journal of clinical microbiology     Volume:  50     ISSN:  1098-660X     ISO Abbreviation:  J. Clin. Microbiol.     Publication Date:  2012 Dec 
Date Detail:
Created Date:  2012-11-19     Completed Date:  2013-04-17     Revised Date:  2013-07-11    
Medline Journal Info:
Nlm Unique ID:  7505564     Medline TA:  J Clin Microbiol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  3952-9     Citation Subset:  IM    
Department of Clinical Laboratory, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antifungal Agents / pharmacology*
Cross Infection / microbiology*
Drug Resistance, Fungal
Epidemiological Monitoring
Fluconazole / pharmacology*
Mycoses / microbiology*
Prospective Studies
Pyrimidines / pharmacology*
Triazoles / pharmacology*
Yeasts / classification,  drug effects*,  genetics,  isolation & purification
Reg. No./Substance:
0/Antifungal Agents; 0/Pyrimidines; 0/Triazoles; 0/voriconazole; 86386-73-4/Fluconazole

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Should varicella-zoster virus culture be eliminated? A comparison of direct immunofluorescence antig...
Next Document:  Chemometric Approach to Selectivity in TLC with Densitometric Detection.